Robert A. Bradway

Chairman and Chief Executive Officer, Amgen. Mr. Bradway has served as Chairman of Amgen Inc. (biotechnology) since January 2013 and as Chief Executive Officer since May 2012. As CEO of Amgen, Inc., he leads a heavily regulated biopharmaceutical company focused on delivering medicines, many of them complex biologics, to millions of patients around the world. Meeting the requirements of numerous safety and regulatory compliance regimes around the world is of utmost importance to Amgen’s patients. Each step of the journey demands careful safety and regulatory oversight to ensure compliance, from the research laboratory where medicines are first imagined and created, to the rigorous manufacturing specifications of biologic medicines, to the marketing and sale of those medicines, and the ongoing post-market pharmacovigilance. Amgen maintains a commitment to the regulatory, safety and compliance requirements. His prior experience at Amgen includes service as President and Chief Operating Officer from May 2010 to May 2012 and as Executive Vice President and Chief Financial Officer from 2007 to 2010.